Celiac disease is of the most common auto-immune diseases in the world. The only current treatment is maintaining a strict gluten-free diet. Join host, Geoff Wall, as he discusses the results of a phase 2 study investigating a novel pharmacologic treatment of Celiac disease.
The GameChanger
Celiac disease is common and has a myriad of symptoms. A new drug may offer a way for patients with Celiac disease to eat gluten without issue.
Show Segments
00:00 - Introductions
00:50 - The Effects of Celiac Disease
03:45 - Why Celiac Causes Problems
09:08 - Latiglutenase Study Background
14:48 - The GameChanger: Latiglutenase Study Results
19:11 - Connecting to Practice
21:31 - Closing Remarks
Host
Geoff Wall, PharmD, BCPS, FCCP, CGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
References and Resources
Murray JA, Syage JA, Wu TT, et al. Latiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge. Gastroenterology. 2022 Dec;163(6):1510-1521.e6. doi: 10.1053/j.gastro.2022.07.071. Epub 2022 Aug 2. PMID: 35931103; PMCID: PMC9707643.
Redeem your CPE or CME here
Get a membership & earn CE for GameChangers Podcast episodes (30 mins/episode)
CE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the extraintestinal manifestations of Celiac disease
2. Discuss the Murray et al study and its implications in patients with Celiac disease
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-024-H01-P
Initial release date: 01/16/2023
Expiration date: 01/16/2024
Additional CPE and CME details can be found here.
Follow CEimpact on Social Media:
LinkedIn
Instagram
Download the CEimpact App for Free Continuing Education + so much more!